US company startrdet a clinical trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Arcutis Biotherapeutics, Inc is starting a new clinical trial of Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis.
The clinical trial started in January 27, 2021 and will continue throughout November 2022.
This study will assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema).
Among the inclusion criteria are:
- Participants legally competent to sign and give informed consent and, if appropriate, assent as required by local laws.
- Males and females, ages 6 years and older at time of signing Informed Consent (Screening).
- Diagnosed with atopic dermatitis 6 months duration (3 months for children), as determined by the Investigator. Stable disease for the past 4 weeks with no significant flares in atopic dermatitis before screening.
- Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline/Day 1. In addition, sexually active FOCBP must agree to use at least one form of a highly effective or barrier method of contraception throughout the trial.
The contacts and locations are the Arcutis Clinical Site 05, San Diego, California, United States; Arcutis Clinical Site 06, San Francisco, California, United States; Arcutis Clinical Site 04, Jacksonville, Florida, United States; Arcutis Clinical Site 01, Tampa, Florida, United States; Arcutis Clinical Site 02, Indianapolis, Indiana, United States; Arcutis Clinical Site 03, Louisville, Kentucky, United States.
For more details: https://ichgcp.net/clinical-trials-registry/NCT04773587
Clinical Research News
Upcoming Clinical Trials
NCT04847206Not yet recruitingConditions: Healthy
NCT04847232Not yet recruitingEffect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)Conditions: Hyperkalemia
NCT04847245Not yet recruitingEsketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive DisorderConditions: Chronic Visceral Pain; Major Depressive Disorder
NCT04847271Not yet recruitingConditions: Obesity, Childhood
NCT04847297Not yet recruitingConditions: Pancreatic Cancer
NCT04847310Not yet recruitingCost-effectiveness Evaluation of the Individual vs Group Transdiagnostic Psychological Treatment for Emotional Disorders in Primary CareConditions: Emotional Disorder; Depression; Somatoform Disorders; Anxiety Disorders
NCT04847401Not yet recruitingConditions: Irritable Bowel Syndrome
NCT04847453Not yet recruitingVenetoclax, Ixazomib Citrate and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain AmyloidosisConditions: Recurrent AL Amyloidosis; Refractory AL Amyloidosis
NCT04847466Not yet recruitingA Phase II Study of Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck CancerConditions: Gastroesophageal Junction (GEJ) Cancers; Advanced HNSCC
NCT04847479Not yet recruitingConditions: Covid19